Humacyte, Inc. (HUMA)
| Market Cap | 123.73M -43.5% |
| Revenue (ttm) | 2.40M +52.5% |
| Net Income | -94.76M |
| EPS | -0.42 |
| Shares Out | 277.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,790,897 |
| Open | 0.5130 |
| Previous Close | 0.5425 |
| Day's Range | 0.4444 - 0.5200 |
| 52-Week Range | 0.3370 - 1.5250 |
| Beta | 2.68 |
| Analysts | Buy |
| Price Target | 1.64 (+268.66%) |
| Earnings Date | Nov 10, 2026 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for HUMA stock is "Buy." The 12-month stock price target is $1.64, which is an increase of 268.66% from the latest price.
News
Humacyte submits ATEV sBLA to FDA
Humacyte (HUMA) announced that it has submitted a supplemental biologics license application, or sBLA, to the FDA for the acellular tissue engineered vessel, or ATEV, seeking approval in arteriovenous...
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
–sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV. –sBLA supported by results from three Phase 3 studies in hemodialysis access.
Humacyte findings show low atherosclerosis susceptibility in ATEV
Humacyte (HUMA) announced new results showing that its acellular tissue engineered vessel, or ATEV, were observed to have low susceptibility to atherosclerosis in patients over multiple years of impla...
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
– Analysis of ATEVs from 52 patients across five clinical trials, some implanted for more than five years, found minimal lipid buildup and no evidence of vulnerable plaques. – First long-term clinical...
Five Presentations, One Leading Innovation: Humacyte's Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
– Presentations include interim Phase 3 results in women, integrated outcomes from three Phase 3 dialysis access trials and long-term human explant data. – Podium presentation to provide an update on ...
Humacyte price target raised to 60c from 50c at Barclays
Barclays analyst Christopher Pasquale raised the firm’s price target on Humacyte (HUMA) to 60c from 50c and keeps an Equal Weight rating on the shares.
Humacyte reports Q3 EPS (6c), consensus (8c)
Reports Q3 revenue $1.03M, consensus $770,000. “During our third quarter, we continued the transformation of our Symvess commercial program in vascular injury repair, doubling revenue over our second ...
Humacyte Earnings Call Transcript: Q3 2026
Symvess sales rose to $1.0M in Q3, with 49 ordering hospitals and Q4 sales expected to at least double. The dialysis sBLA was targeted for November, and the first CTEV CABG study began screening patients.
Humacyte Earnings release: Q3 2026
Humacyte released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Humacyte Quarterly report: Q3 2026
Humacyte has published its Q3 2026 quarterly earnings report on November 10, 2026.
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
– Commercial adoption of Symvess® accelerated during the third quarter with sales totaling $1.0 million, a 151% increase over the 2 nd quarter. – Symvess commercial momentum continued into the fourt...
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
– Humacyte has initiated the CABG clinical study and looks forward to the commencement of screening for potential patients. – “Moving it into a first-in-human study is the step that will tell us whet...
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
– Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Humacyte issued new U.S. patent covering Symvess
Humacyte (HUMA) announced the issuance of a new U.S. patent covering key aspects of the manufacturing, sterilization, storage and shipping of Symvess and other bioengineered human tissues. U.S. Patent...
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C.
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider ...
Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49
Humacyte (HUMA) provided a commercial update highlighting increasing momentum in the launch of Symvess, its FDA-approved acellular tissue engineered vessel for vascular trauma. The number of hospitals...
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven...
Humacyte initiated with an Equal Weight at Barclays
Barclays initiated coverage of Humacyte (HUMA) with an Equal Weight rating and 50c price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
Humacyte announces addition of Coward, Kuznik to board
Humacyte (HUMA) announced the addition of Scott Coward and Paul Kuznik to the Company’s Board of Directors. Scott Coward served as Executive Vice President, Chief Legal Officer, Chief Administrative O...
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Symvess, an FDA-approved bioengineered vessel, is expanding from trauma to dialysis and cardiovascular markets, with a supplemental BLA for dialysis access planned for November 2026 and CABG trials starting in 2026. Commercial efforts are being rebuilt, and financial runway extends into late 2027.
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte announces FDA extension of expiration dating period for Symvess
Humacyte (HUMA) announced that the FDA has authorized an extension of the expiration dating period for Symvess from 18 months to 36 months when stored refrigerated at 2 degrees C…